Kubota Pharmaceutical Holdings Co. Ltd. operates as a holding company which provides the management of its subsidiaries. The company is also involved in the developing patient based ophthalmology suite to detect nascent disease progression to enhance treatment outcome in patients with wet AMD (Age-related Macular Degeneration), DME (Diabetic Macular Edema) and other neovascular retinal diseases. It also provides the research, development, export, import, manufacture and sale of pharmaceutical products worldwide. The company was founded on December 11, 2015 and is headquartered in Tokyo, Japan.